按ISO 15189:2012记录计量溯源性:实施与审核的共识声明
本文为ISO 15189:2012中计量溯源性要求的实施与审核共识。指出许多被测量无高于厂家测量程序或工作校准品的参考,免疫分析因分析选择性差异及参考物质不可互换导致结果不同;实验室应获得校准品赋值不确定度信息,IVD提供者应告知批间变异最坏情况;辅助设备需验证校准,其关键性可通过基于风险分析的方法评估。
要点
- 实验室应记录结果计量溯源性,但许多被测量无高于厂家方法的参考。
- 免疫分析因选择性差异或参考物质不可互换可产生不同结果。
- 应获取校准品赋值不确定度及批间变异最坏情况信息。
核心结论
- 医学实验室应按ISO 15189:2012记录计量溯源性,认可机构据此评估。
- 当无更高参考时,溯源性止于厂家测量程序与工作校准品。
研究设计与样本
- ISO 15189:2012计量溯源性要求的实施与审核共识声明。
主要发现
- 部分免疫分析即使测同一量或引用同一参考物质,因分析选择性差异结果不同。
- 参考物质不可互换也是结果差异的原因。
- 临床样品测量不确定度受溯源链所有更高步骤不确定度影响。
- 校准品赋值批间变异表现为长期不精密度的一部分。
关键数值与推荐
- 实验室应获得所用商业校准品赋值不确定度的充分适宜信息。
- IVD提供者应告知终端用户预期批间变异的最坏情况。
- 辅助设备需验证其正确校准,关键性可用基于风险分析的方法评估。
临床怎么用
- 实验室应记录并审核结果计量溯源性,获取校准品赋值不确定度信息。
- 对可能关键影响结果的辅助设备验证校准并评估其不确定性贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ISO15189:2012 requires medical laboratories to document metrological traceability of their results. While the ISO17511:2003 standard on metrological traceability in laboratory medicine requires the use of the highest available level in the traceability chain, it recognizes that for many measurands there is no reference above the manufacturer's selected measurement procedure and the manufacturer's working calibrator. Some immunoassays, although they intend to measure the same quantity and may even refer to the same reference material, unfortunately produce different results because of differences in analytical selectivity as manufacturers select different epitopes and antibodies for the same analyte. In other cases, the cause is the use of reference materials, which are not commutable. The uncertainty associated with the result is another important aspect in metrological traceability implementation. As the measurement uncertainty on the clinical samples is influenced by the uncertainty of all steps higher in the traceability chain, laboratories should be provided with adequate and appropriate information on the uncertainty of the value assignment to the commercial calibrators that they use. Although the between-lot variation in value assignment will manifest itself as part of the long-term imprecision as estimated by the end-user, information on worst-case to be expected lot-lot variation has to be communicated to the end-user by the IVD provider. When laboratories use ancillary equipment that potentially could have a critical contribution to the reported results, such equipment needs verification of its proper calibration and criticality to the result uncertainty could be assessed by an approach based on risk analysis, which is a key element of ISO15189:2012 anyway. This paper discusses how the requirement for metrological traceability as stated in ISO15189 should be met by the medical laboratory and how this should be assessed by accreditation bodies.
引用
- Thelen M, Vanstapel F, Brguljan PM, et al. Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element. Clin Chem Lab Med. 2019. PMID: 30511927. doi:10.1515/cclm-2018-1212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。